-
-
7 . Periodical
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
- 저자
- by Danese, Silvio; Panaccione, Remo; Feagan, Brian G; Afzali, Anita; Rubin, David T, et al.
- 소스
- The Lancet Gastroenterology & Hepatology; February 2024, Vol. 9 Issue: 2 p133-146, 14p